Halozyme Appoints Former J&J Pharma CFO Darren Snellgrove as New Chief Financial Officer

summarizeSummary

Halozyme Therapeutics announced the appointment of Darren Snellgrove, a former Johnson & Johnson executive, as its new Chief Financial Officer, effective June 8, 2026, signaling a strengthening of its financial leadership.

check_boxKey Events

• New Chief Financial Officer Appointed

  Darren Snellgrove has been appointed as Halozyme's Chief Financial Officer, effective June 8, 2026. He will lead financial operations, strategy, capital allocation, corporate development, and investor relations.

• High-Caliber Executive from Johnson & Johnson

  Mr. Snellgrove brings over 30 years of financial leadership, most recently serving as VP, Investor Relations at Johnson & Johnson, and previously as CFO of J&J's Pharmaceutical sector, which generated over $50 billion in annual revenue.

• Substantial Compensation Package

  Snellgrove's compensation includes an annual salary of $670,000, a bonus target of 50% of his base salary, and new-hire equity awards totaling $7.2 million (comprising $3.2 million in RSUs and $4.0 million in stock options). He will also receive a $350,000 sign-on cash bonus.

• Interim CFO Transition

  David Ramsay, the current Interim CFO, will transition to an advisory role to assist during a brief transition period, effective June 8, 2026.

auto_awesomeAnalysis

Halozyme Therapeutics has appointed Darren Snellgrove, a seasoned finance leader with extensive experience from Johnson & Johnson, as its new Chief Financial Officer. This move is significant as it brings a high-caliber executive to lead the company's financial operations and strategy, including capital allocation, corporate development, and investor relations. The substantial compensation package, including $7.2 million in new-hire equity and a $350,000 sign-on bonus, underscores the company's commitment to attracting top talent and the strategic importance of this role. Snellgrove's background as CFO of J&J's Pharmaceutical sector suggests a focus on robust financial management and strategic growth within the life sciences industry.